CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial.

ABSTRACT:

Background

Worldwide, over 10 million people are killed or hospitalized because of traumatic brain injury each year. About 90% of deaths occur in low- and middle-income countries. The condition mostly affects young adults, and many experience long lasting or permanent disability. The social and economic burden is considerable. Tranexamic acid (TXA) is commonly given to surgical patients to reduce bleeding and the need for blood transfusion. It has been shown to reduce the number of patients receiving a blood transfusion by about a third, reduces the volume of blood transfused by about one unit, and halves the need for further surgery to control bleeding in elective surgical patients.

Methods/design

The CRASH-3 trial is an international, multicenter, pragmatic, randomized, do

SUBMITTER: Dewan Y 

PROVIDER: S-EPMC3481366 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature